SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is drawing significant attention for its expanding multi-chain utility and growing daily fee revenue, with the community actively speculating on an imminent price breakout to "drop a zero" as it sees aggressive buying. Despite this bullish sentiment and new exchange listings, a segment of the community cautions that it may be a pump and dump.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is rallying sharply following a preliminary Q3 revenue pre-announcement that significantly exceeded both previous guidance and analyst consensus, igniting community excitement and reinforcing its role as a key "picks and shovels" beneficiary in the accelerating AI infrastructure build-out.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an accounting review citing material weaknesses and delayed financial filings, causing a sharp stock plunge as the community debates whether the steep sell-off is an overreaction or a severe governance concern.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function, enabling patients with these disorders to live fuller and healthier lives. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

AgomAb Therapeutics NV - ADR

AgomAb Therapeutics NV (AGMB), a recent IPO, is a major talking point due to its extreme volatility and rapid price movements, with community conversation heavily focused on a potential low float and the ongoing short squeeze narrative.

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Roivant Sciences Ltd

Roivant Sciences is drawing attention after reporting positive Phase 3 data for its dermatomyositis drug brepocitinib and divesting Dermavant, which has bolstered its significant cash reserves. The community is keenly discussing the substantial upside potential from ongoing LNP patent litigation involving major pharmaceutical companies, where Roivant holds a key interest through its Genevant stake.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is currently drawing attention due to its community's strong promotion of its 'third frog' narrative, positioning it as a direct representation of Pepe's 4chan origins and a prime beta play to $PEPE. While detractors label it 'worthless garbage' and a 'scam,' its dedicated, community-owned movement consistently highlights its resilience in challenging market conditions and its potential for substantial growth.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display Technologies, Specialty Materials, Environmental Technologies, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computer, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Environmental Technologies segment focuses on manufacturing ceramic substrates and filter products for emissions control in mobile applications. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning (GLW) is trending after a significant agreement with Meta Platforms to supply fiber optics for AI data centers, firmly establishing its role as a critical infrastructure provider. The community is actively discussing its potential as a long-term wealth builder, driven by its diverse portfolio supporting the AI buildout and its continued ascent to new highs.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending sharply higher after reporting strong results, with its energy and transportation segments seeing significant growth attributed to booming AI-driven data center demand. While bullish investors celebrate record backlogs and a market rotation into industrials, a vocal segment expresses skepticism about the valuation and potential for a significant pullback.

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Viatris Inc

Viatris is trending as investors debate its deep value and strategic pivot through new product launches like Inpefa internationally and active share buyback programs, while others remain cautious given past underperformance and persistent concerns over operational headwinds like the Indore facility.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Investors are heavily anticipating Upstart's upcoming earnings report, with community sentiment sharply divided between hopes for a rebound based on its AI lending technology and deep concerns over recent sector underperformance and management's perceived lack of shareholder focus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now

Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Retail chatter around Creative Medical Technology Holdings picked up on Wednesday after the company said the U.S. Food and Drug Administration (FDA)&nbsp;had granted Fast Track status to its lead experimental treatment, CELZ-201-DDT, for degenerative disc disease (DDD), which is a leading cause of chronic lower back pain and disability.<a href="https://stocktwits.com/symbol/CELZ">Creative Medical’s stock</a> rose 4.70% to $3.23 on Wednesday before slipping 2.8% in after-hours trading.The Fast Track designation is reserved for treatments that have the potential to address serious health conditions with limited existing treatment options.&nbsp;It allows for more frequent contact with the FDA, rolling submissions of the company’s Biologics License Application, and the possibility of priority review, potentially speeding the path to market.CELZ-201-DDT is part of Creative Medical’s AlloStem platform and uses allogeneic perinatal cells, delivered through minimally invasive, ultrasound-guided intramuscular injections.&nbsp;&nbsp;The FDA's decision was based on clinical data that demonstrated the treatment's safety and evidence that the therapy may help patients.&nbsp;CEO Timothy Warbington said the designation was not only a scientific validation, but also a milestone that could accelerate development and address the unmet need for novel, non-addictive therapies for back pain at a time when the U.S. is in the midst of an opioid crisis.DDD affects millions worldwide, with current care often limited to pain management or surgery. Creative Medical is aiming to treat the root causes, which are degeneration and inflammation, rather than just the symptoms.&nbsp;The company stated that the potential market for innovative therapies for spinal disorders could reach over $20 billion by 2030.Within 15 days, Creative Medical will post its expanded access policy for CELZ-201-DDT.On Stocktwits, retail sentiment for Creative Medical was ‘extremely bullish’ amid a 3,600% surge in 24-hour message volume.One user said they were adding to their Creative Medical position on every dip, expecting the stock to move above 4.&nbsp;<stembedurl>https://stocktwits.com/Dickman777/message/624985970</stembedurl>Another user said that if there is little to no new dilution, the shares should be trading at 32 rather than 3.20.<stembedurl>https://stocktwits.com/Peterb3346/message/624989829</stembedurl>Creative Medical’s stock has risen nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Creative Medical Technology Holdings (CELZ) picked up on Wednesday after the company said the U.S. FDA had granted Fast Track status to CELZ-201-DDT. (Photo credit: Getty Images)

Retail Traders Pile Into Creative Medical After FDA Fast Tracks Degenerative Disc Disease Therapy

The company estimates that the potential market for innovative treatments for spinal disorders could exceed $20 billion by 2030.

Equity

New Strong Sell Stocks for July 31st

CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

Creative Medical Technology Holdings Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$1.90
Prev Close	$1.93
Open	$1.92
Dividend Yield	0.00%
50-Day Moving Average	$2.14
Beta	0.91
Avg. Volume	150,572.90
PE Ratio	-0.66

52-Week High	$6.90
52-Week Low	$1.50
Market Capitalization	$4.98M
EPS (Annual)	-$3.71
Price to Book	0.89
Revenue Per Employee	$2,750.00
Enterprise Value/EBITDA	N/A

CELZ
Creative Medical Technology Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CELZ News

CELZCreative Medical Technology Holdings Inc